.PNG&w=256&q=75)
Sai Parenteral's
Mainboard₹ NaN / N/A Shares
Sai Parenteral's IPO Details
The Sai Parenteral's IPO price band is set between ₹372-392 per equity share, with a face value of ₹5 per share. The issue is managed by Bigshare Services Pvt.Ltd., and the equity shares are proposed to be listed on the Mainboard.
The IPO date for subscription opens on 24 Mar, 2026 and closes on 27 Mar, 2026. Investors can check the allotment status on 30 Mar, 2026, while the listing date is tentatively scheduled for 2 Apr, 2026.
The total issue size is 1,04,28,288 shares, aggregating up to ₹408.79 crore. Stay tuned for the latest Sai Parenteral's IPO review and GMP updates.
Sai Parenteral's IPO Review, Rating & Analysis
Sai Parenteral's IPO Review
NO REVIEWSai Parenteral's IPO Rating
Sai Parenteral's IPO Highlights
IPO Date
Mar 24, 2026 - Mar 27, 2026
Listing Date
2 Apr, 2026
Face Value
₹5 Per Equity Share
Price Band
₹372-392 per equity share
Lot Size
-
Fresh Issue
Shares
Offer for Sale
-
Listing At
BSE, NSE
Sai Parenteral's IPO Timeline
Issue Price
₹372-392 per equity shareFace Value
₹5 Per Equity ShareListing at Group
BSE, NSERegistrar
Bigshare Services Pvt.Ltd.Lead Manager
Arihant Capital Markets Ltd.Issue Size
1,04,28,288 shares(aggregating up to ₹408.79 crore)Sai Parenteral's IPO Financial Information
| Period Ended | Assets | Revenue | Profit After Tax | Net Worth | Reserves and Surplus | Total Borrowing |
|---|---|---|---|---|---|---|
| 30-Sep-25 | 376.24 | 89.43 | 7.76 | 209.37 | 188.84 | 76.07 |
| 31-Mar-25 | 272.39 | 163.74 | 14.43 | 95.78 | 80.36 | 93.95 |
| 31-Mar-24 | 268.10 | 155.18 | 8.42 | 76.40 | 61.30 | 118.79 |
| 31-Mar-23 | 133.96 | 97.03 | 4.38 | 31.49 | 24.34 | 68.55 |
In Cr.
Sai Parenteral's IPO Valuations
EPS Pre IPO
₹/-EPS Post IPO
₹/-PE Pre IPO
-PE Post IPO
-ROE
16.82%ROCE
28.92%Debt Equity
-RoNW
15.09%PAT Margin
8.88%Price to Book Value
-Promoters & Share Holding
Promoter(s) Name
- Anil Kumar Karusala
- Vijitha Gorrepati
- Karusala Aruna
| Share Holding Pre Issue | Share Holding Post Issue |
|---|---|
| N/A% | N/A% |
About Company
Established in 2001, Sai Parenteral's Ltd. is a diversified pharmaceutical formulations company with expertise in research and development and manufacturing.
The company has two business segments: Branded Generic Formulations and Contract Development and Manufacturing Organisation (CDMO) products and services.
The company’s product portfolio covers a wide spectrum of pharmaceutical formulations in various therapeutic areas such as cardiovascular, neuropsychiatry, anti-diabetic agents, respiratory health, antibiotics, gastroenterology, vitamins, minerals, and supplements (VMS), analgesics, and dermatology in various dosage forms such as injectables, tablets, capsules, liquid orals, and ointments.
The company’s customer base comprises central and state government departments, pharmaceutical companies, public and private sector hospitals, and super stockists across India. Sai Parenteral’s started its export business in FY 2023 after acquiring two international accredited facilities in Hyderabad, Telangana, and currently serves regulated and semi-regulated markets such as Australia, New Zealand, Southeast Asia, Middle East, and Africa.
The company has five manufacturing facilities in India. Four are located in Hyderabad, Telangana. These are a GMP compliant injectable facility, a WHO-GMP injectable facility, a TGA-Australia and PIC/S accredited solid oral dosage facility, and a WHO-GMP cephalosporin facility. The company’s wholly owned subsidiary has a GMP certified facility located in Ongole, Andhra Pradesh.
As of August 31, 2025, Sai Parenteral's Ltd. had 277 full-time employees.
Sai Parenteral's IPO - Issue Objectives & Utilisation of proceeds
| Objectives | Amount |
|---|---|
| Capacity expansion and upgradation of manufacturing facilities | - |
| Establishment of a new R&D Centre | - |
| Repayment / prepayment of certain outstanding borrowings | - |
| Working capital requirements | - |
| Investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the proposed acquisition of Noumed Pharmaceuticals Pty Limited (Australia) | - |
| General corporate purposes | - |
Company Contact Details
Sai Parenteral's
Plot No 39, 5th Floor, Lavanya Arcade, Jayabheri Enclave, Gachibowli, K.V. Rangareddy, Seri Lingampally, Hyderabad, Telangana - 500032.Registrar Contact Details
Bigshare Services Pvt Ltd
Phone: +91-22-6263 8200
Email: ipo@bigshareonline.com
Frequently Asked Questions about Sai Parenteral's IPO
When will Sai Parenteral's IPO open for subscription?
The Sai Parenteral's IPO opens on 24 Mar, 2026 and closes on 27 Mar, 2026.
What is the investors portion for Sai Parenteral's IPO?
The investors' portion for QIB is N/A%, NII is N/A%, and Retail is N/A%.
How to apply for Sai Parenteral's IPO?
You can apply for Sai Parenteral's IPO via ASBA online through your bank account. You can also apply via UPI through stock brokers like Zerodha, Upstox, or Paytm Money.
What is the issue size of Sai Parenteral's IPO?
The issue size of Sai Parenteral's IPO is approx ₹1,04,28,288 shares(aggregating up to ₹408.79 crore) crores.
What is the price band of Sai Parenteral's IPO?
The price band for Sai Parenteral's IPO is ₹372 to ₹392 per equity share.
What is the lot size of Sai Parenteral's IPO?
The minimum bid (lot size) for Sai Parenteral's IPO is 38 shares with an investment of approx ₹ NaN .
What is the allotment date of Sai Parenteral's IPO?
The allotment date for Sai Parenteral's IPO is 30 Mar, 2026.
What is the listing date of Sai Parenteral's IPO?
The listing date for Sai Parenteral's IPO is expected to be 2 Apr, 2026.
What is the GMP of Sai Parenteral's IPO?
The latest Grey Market Premium (GMP) for Sai Parenteral's IPO is being updated regularly on IPOROCK.
Parth D.
Founder & Lead Analyst
Parth D. is a software engineer and financial analyst who brings a quantitative edge to IPO tracking. With deep expertise in algorithmic trading and financial tool development, he builds the technology that powers IPORock's real-time data engines. He has been tracking the Indian market since 2018.